Maxim lowered the firm's price target on Aytu BioPharma to $7 from $9 and keeps a Buy rating on the shares. The firm cites the company's Q4 and adjusted EBITDA miss, and while the quarter was the 9th straight quarter of positive adjusted EBITDA, its base business - ADHD+pediatrics - has effectively peaked, the analyst tells investors in a research note. Maxim adds however that in June, Aytu announced it signed an exclusive commercialization agreement with Fabre-Kramer Pharmaceuticals to commercialize EXXUA, and the firm believes that EXXUA is a transformational asset that can accelerate growth beyond the current ADHD franchise.
